A/T Polymorphism
|
| |
A/A |
A/T and T/T |
TT |
 2 |
P value |
| PC |
87 |
0 |
0 |
... |
... |
| BPH |
40 |
0 |
0 |
... |
... |
Controls
|
96
|
0
|
0
|
...
|
...
|
V/L Polymorphism
|
| |
V/V |
V/L |
L/L |
2 |
P value |
| PC |
25 (28.74) |
39 (44.83) |
23 (26.44) |
0 |
1 |
| BPH |
12 (30) |
16 (40) |
12 (30) |
.03 |
.86 |
Controls
|
29 (30.20)
|
42 (43.75)
|
25 (26.04)
|
...
|
...
|
(TA)n Polymorphism
|
| |
(TA)0/(TA)0 |
(TA)0/(TA)9 |
TA)9/(TA)9 |
|
|
| PC |
84 (96.55) |
2 (2.30) |
1 (1.15) |
... |
... |
| BPH |
40 (100) |
0 (0) |
0 (0) |
... |
... |
Controls
|
96 (100)
|
0 (0)
|
0 (0)
|
...
|
...
|
|
| Abbreviations: A, alanine (wild-type alleles); BPH, benign prostatic
hyperplasia; L, leucine; PC, prostate cancer; T, threonine; V, valine
(wild-type allele). |
| aThe 2 and the respective P values for the V89L
polymorphism were calculated for PC cases vs control and for BPH cases vs
controls separately. For this purpose, the 3 genotypes at this site were
classified into 2 groups for both the cases and the controls: high activity
(Val/Val) and low activity (Val/Leu and Leu/Leu). |
|
